(Q44264762)

1 December 2017

0 references

Low-density lipoprotein lowering therapy: an analysis of the options (English)

1 reference

1 December 2017

1 reference

Frank M Sacks

1

1 reference

1 December 2017

language of work or name

English

0 references

publication date

1 December 2002

1 reference

Journal of the American College of Cardiology

1 December 2017

published in

1 reference

1 December 2017

volume

40

1 reference

1 December 2017

issue

12

1 reference

1 December 2017

page(s)

2135-2138

1 reference

Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels. The Prospective Pravastatin Pooling project

1 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902609-8

7 January 2021

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902609-8

7 January 2021

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902609-8

7 January 2021

Reduction of stroke events with pravastatin: the Prospective Pravastatin Pooling (PPP) Project

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902609-8

7 January 2021

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902609-8

7 January 2021

Cholesterol-lowering effects of dietary fiber: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902609-8

7 January 2021

Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902609-8

7 January 2021

Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902609-8

7 January 2021

Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902609-8

7 January 2021

Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902609-8

7 January 2021

Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902609-8

7 January 2021

Disposition of the selective cholesterol absorption inhibitor ezetimibe in healthy male subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902609-8

7 January 2021

The plasma concentration and LDL-C relationship in patients receiving ezetimibe

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902609-8

7 January 2021

Inhibition of intestinal cholesterol absorption by ezetimibe in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902609-8

7 January 2021

Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902609-8

7 January 2021

Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902609-8

7 January 2021

Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902609-8

7 January 2021

Carcinogenicity of lipid-lowering drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902609-8

7 January 2021

Cholesterol lowering and mortality: the importance of considering initial level of risk

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902609-8

7 January 2021

Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902609-8

7 January 2021

Dose-response characteristics of cholesterol-lowering drug therapies: implications for treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902609-8

7 January 2021

Clinical trial experience with extended-release niacin (Niaspan): dose-escalation study.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902609-8

7 January 2021

Comparison of efficacy and safety of atorvastatin and simvastatin in patients with dyslipidemia with and without coronary heart disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902609-8

7 January 2021

Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902609-8

7 January 2021

Design of the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT)-TIMI 22 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902609-8

7 January 2021

Physicians' interpretation of "class effects": a need for thoughtful re-evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902609-8

7 January 2021

"The lower the better" in hypercholesterolemia therapy: a reliable clinical guideline?.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902609-8

7 January 2021

Efficacy and safety of simvastatin 80 mg/day in hypercholesterolemic patients. The Expanded Dose Simvastatin U.S. Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902609-8

7 January 2021

An overview of the clinical safety profile of atorvastatin (lipitor), a new HMG-CoA reductase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902609-8

7 January 2021

ACC/AHA/NHLBI clinical advisory on the use and safety of statins

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902609-8

7 January 2021

10.1016/S0735-1097(02)02609-8

Identifiers

DOI

1 reference

1 December 2017

1 reference